ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japan eyes COVID antibody cocktail for homebound patients

Health ministry weighs care options outside hospitals amid bed shortage

The antibody treatment developed by U.S. company Regeneron was used to treat former President Trump.   © Reuters

TOKYO -- Japan's health ministry is working to approve at-home use of the COVID-19 antibody cocktail available to inpatients, as the country's surge in new cases forces many hospitals to reserve beds only for the sickest.

The treatment, developed by U.S.-based Regeneron Pharmaceuticals, is believed to reduce the risk of severe symptoms and death by 70%. The medication is geared toward patients with mild to moderate symptoms, and it is largely administered via IV drip to high-risk groups like the elderly and those with preexisting conditions.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more